Dusseldorf - Delayed Quote EUR

Akeso Inc (4RY.DU)

11.10

-0.10

(-0.89%)

At close: April 25 at 7:30:13 PM GMT+2

Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today

Both U.S.-based Summit Therapeutics (NASDAQ: SMMT) and BioNTech (NASDAQ: BNTX) were down significantly, plunging 36.1% and 15.4%, respectively, in Friday's trading. The severe moves were likely related to a Chinese rival in the PD-1/VEGF bispecific antibody area, Akeso (OTC: AKES.F), receiving FDA approval for a cancer drug that utilizes similar technology, as well as an additional approval in China. As a result, Akeso shares were up 11.7% on Friday.

Motley Fool 2 days ago

SMMT

BNTX

AKESF
Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical Products Administration (NMPA) for its supplementary New Drug Application (sNDA) for use as a monotherapy for the first-line treatment of PD-L1-positive (TPS ≥ 1%) non-small cell lung cancer (NSCLC) in patients who are negative for epidermal growth factor receptor (EGFR) gene mutations and anaplastic l

PR Newswire 2 days ago

AKESF
FDA approves Akeso’s monoclonal antibody for nasopharyngeal carcinoma

The approval is supported by the outcomes from the AK105-202 trial and the Phase III study. AK105-304.

Pharmaceutical Technology 2 days ago

AKESF
Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) has approved its differentiated PD-1 monoclonal antibody, penpulimab-kcqx, in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or a

PR Newswire 3 days ago

AKESF
Akeso and Summit notch another Phase III win with their Keytruda competitor

Akeso and Summit's drug previously beat Keytruda in a separate Phase III study, extending PFS by five months.

Clinical Trials Arena 3 days ago

AKESF

GLDAF

SMMT
Why Is Summit Therapeutics Stock Soaring On Wednesday?

Summit Therapeutics Inc.'s (NASDAQ:SMMT) partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday. The trial is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. HARMONi-6 is a study conducted in China sponsored

Benzinga 4 days ago

SMMT

AKESF

PFE
Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is both pleased and honored to announce that its global first-in-class PD-1/VEGF bispecific antibody, ivonescimab, in combination with chemotherapy, has demonstrated strongly positive results in the Phase III clinical trial (AK112-306/HARMONi-6) for first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC). The Independent Data Monitoring Committee (IDMC) declared that the study had met its primary endpoint of progression-fre

PR Newswire 5 days ago

AKESF
Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the National Medical Products Administration (NMPA) for the treatment of moderate-to-severe plaque psoriasis in adult patients.

PR Newswire 9 days ago

AKESF
3 Asian Stocks Estimated To Be Up To 42.1% Below Intrinsic Value

Amidst ongoing trade tensions and economic policy shifts, Asian markets have shown resilience with indices like Japan's Nikkei 225 and China's CSI 300 posting gains. In this environment, identifying stocks that are undervalued compared to their intrinsic value can be a strategic approach for investors seeking opportunities amidst market fluctuations.

Simply Wall St. 9 days ago

YSHLF

AKESF
Asian Growth Stocks With High Insider Ownership In April 2025

As global markets navigate a landscape marked by trade uncertainties and monetary policy shifts, Asia's economic resilience continues to capture investor attention. In this environment, growth companies with high insider ownership can offer appealing insights into potential stability and alignment of interests between management and shareholders.

Simply Wall St. 9 days ago

AKESF
The Chinese CEO Who Believes Her Cancer Drug Can Beat Merck’s Bestseller

Michelle Xia represents a rising generation of biotech companies in China challenging Western giants.

The Wall Street Journal 16 days ago

AKESF
High Growth Tech Stocks In Asia To Watch March 2025

Amidst global economic uncertainty and inflation concerns, Asian markets have shown resilience, with key indices maintaining stability despite external pressures such as U.S. trade policies and fluctuating consumer sentiment. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate strong fundamentals and adaptability to changing market conditions, making them worthy of attention in the evolving landscape.

Simply Wall St. 28 days ago

AKESF
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies

Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.

PR Newswire 28 days ago

AKESF
Akeso to Host 2024 Full-Year Financial Results and Corporate Update Call on Monday, March 31, 2025

Akeso Inc. (9926.HK) ("the Company") will hold a conference call to discuss its full-year 2024 results on Monday, March 31, 2025, at the following times:

PR Newswire 30 days ago

AKESF
Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting

Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab (AK104), in combination with concurrent chemoradiotherapy (CCRT) for the treatment of locally advanced cervical cancer.

PR Newswire last month

AKESF
Asian Growth Companies Insiders Are Eager To Own

In the midst of global economic uncertainties and trade tensions, Asian markets have shown resilience with modest gains in regions like Japan, while China remains focused on boosting consumption to drive growth. In such a landscape, companies with high insider ownership often signal confidence from those closest to the business, making them intriguing prospects for investors seeking growth opportunities.

Simply Wall St. last month

AKESF
AAC Technologies Holdings And 2 Other Asian Stocks Estimated To Be Trading Below Their Intrinsic Values

As global markets grapple with trade uncertainties and inflation concerns, Asian equities have shown resilience, with Japan's stock markets experiencing modest gains and China's indices rising on stimulus hopes. In such a fluctuating environment, identifying stocks that are potentially trading below their intrinsic values can offer investors opportunities to capitalize on market inefficiencies.

Simply Wall St. last month

AKESF

AACAF

AACAY
Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for the first-line treatment of recurrent or metastatic nasopharyngeal cancer (NPC) in combination with chemotherapy.

PR Newswire last month

AKESF
Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy compared to pembrolizumab monotherapy in the first-line treatment of PD-L1 positive (PD-L1 TPS ≥1%) locally advanced or metastatic non-small cell lung cancer (NSCLC) have been published in The Lancet.

PR Newswire last month

AKESF
Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab, the world's first PD-1/CTLA-4 bispecific antibody independently developed by the company, as an adjuvant treatment for hepatocellular carcinoma (HCC) with high recurrence risk following curative resection or ablation.

PR Newswire last month

AKESF

Performance Overview

Return	4RY.DU	HANG SENG INDEX (^HSI)
YTD	+54.17%	+9.58%
1-Year	+105.56%	+27.17%
3-Year	+620.78%	+10.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Akeso Inc (4RY.DU)

Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today

Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab

FDA approves Akeso’s monoclonal antibody for nasopharyngeal carcinoma

Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

Akeso and Summit notch another Phase III win with their Keytruda competitor

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy

Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis

3 Asian Stocks Estimated To Be Up To 42.1% Below Intrinsic Value

Asian Growth Stocks With High Insider Ownership In April 2025

The Chinese CEO Who Believes Her Cancer Drug Can Beat Merck’s Bestseller

High Growth Tech Stocks In Asia To Watch March 2025

Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies

Akeso to Host 2024 Full-Year Financial Results and Corporate Update Call on Monday, March 31, 2025

Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting

Asian Growth Companies Insiders Are Eager To Own

AAC Technologies Holdings And 2 Other Asian Stocks Estimated To Be Trading Below Their Intrinsic Values

Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet

Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

Performance Overview